MindBio Therapeutics Corp (CSE: MBIO) Reveals Scientific Paper in World-First Take-Home, LSD-Microdosing Clinical Trial in 80 Healthy Participants
May 09 2023 - 9:13AM
InvestorsHub NewsWire
![](https://investorshub.advfn.com/uimage/uploads/2023/5/9/sxllsScreenshot_2023-05-09_at_14.11.02.png)
MindBio Therapeutics Corp (CSE:
MBIO) Reveals Scientific Paper in World-First Take-Home,
LSD-Microdosing Clinical Trial in 80 Healthy Participants
-
MindBio clinical trial published
in Peer Reviewed Paper Biological Psychiatry
-
First of 8 significant
publications on LSD-Microdosing from a Phase 1 clinical
trial
-
Phase 1 Clinical trial
produced outstanding mood
responses in healthy
participants
-
MindBio is developing a
Microdosing treatment protocol combining big data and drug and
formulation development.
Vancouver,
British Columbia – May 9, 2023 -- InvestorsHub NewsWire
-- MindBio Therapeutics Corp.
(CSE: MBIO); (the
"Company"
or "MindBio")
is pleased to announce its scientific collaborators have recently
published their first Peer Reviewed Paper in Biological Psychiatry,
an official journal of Psychiatric Neuroscience and Therapeutics.
MindBio scientific collaborators expect to publish a further 7
important scientific papers in the coming year, announcing
significant findings from the substantial amount of data collected
from wearables, blood and DNA analysis, EEG and other biometric and
psychometric data collected from the Phase 1 trial.
Having completed the world's
first government approved take-home LSD-Microdosing clinical trial,
this peer reviewed scientific paper, examines the effectiveness of
LSD-Microdosing in a non-clinical laboratory environment, where
healthy participants self-administered the drug at home under
double blinded and placebo controlled conditions.
The Phase 1 LSD-Microdosing
clinical trial of healthy volunteers were randomised into an LSD
group and a Placebo group and received 14 doses every 3 days for 6
weeks.
With the first dose conducted in
the laboratory, the remaining 13 doses were taken at
home.
Notably, there were no serious
adverse events recorded and participants on dose days had
substantial improvements in mood including increases in:
-
Energy
-
Social Connectivity
-
Creativity
-
Wellness
-
Happiness
Chief Executive Justin Hanka said
"The data we have collected in our clinical trials has exceeded our
expectations and shows much promise for treating patients with
mental health conditions such as depression and anxiety where
diminished mood, compromised wellbeing and low energy are
experienced.
The data is confirmatory of our
dedication to progress clinical trials in continuation Phase 2
LSD-Microdosing clinical trials, particularly in patients
experiencing depressive symptoms".
MindBio is fully funded for two
upcoming Phase 2 clinical trials LSD-Microdosing in patients with
Major Depressive Disorder and a second Phase 2 clinical trial in
cancer patients experiencing emotional distress.
Receive our latest updates
here:
Register
to receive our latest updates
Follow
MindBio on LinkedIn:
here
Follow
CEO Justin Hanka on LinkedIn:
here
For
further information, please contact:
Justin
Hanka, Chief Executive Officer
61
433140886
justin@mindbiotherapeutics.com
About MindBio
Therapeutics
MindBio is a
biotech/biopharma company focused on creating novel and emerging
treatments for mental health conditions and is conducting world
first take home LSD-Microdosing human clinical
trials. MindBio has a leading
presence in microdosing of psychedelic medicines and is advancing
its drug and technology intervention protocols through clinical
trials. MindBio has developed a multi-disciplinary platform for
developing treatments and is involved in psychedelic medicine
development, has completed Phase 1 clinical trials microdosing
Lysergic Acid Diethylamide (LSD) in 80 patients, has a Phase 2
clinical trial in development microdosing LSD in patients with
Major Depressive Disorder and a Phase 2 clinical trial in
development microdosing LSD in late stage cancer patients
experiencing existential distress. MindBio invests in research that
forms the basis for developing novel and clinically proven
treatments including digital technologies and interventions to
treat debilitating health conditions such as depression, anxiety
and other related mental health conditions.
Cautionary Note Concerning
Forward-Looking Statements:
The press release contains
"forward-looking statements" within the meaning of applicable
securities laws. Forward-looking statements can be identified by
words such as: "anticipate," "intend," "plan," "budget," "believe,"
"project," "estimate," "expect," "scheduled," "forecast,"
"strategy," "future," "likely," "may," "to be," "could," "would,"
"should," "will" and similar references to future periods or the
negative or comparable terminology, as well as terms usually used
in the future and conditional. Forward-looking statements are based
on assumptions as of the date they are provided. However, there can
be no assurance that such assumptions will reflect the actual
outcome of such items or factors.
Additionally, there are known and
unknown risk factors that could cause the Company's actual results
and financial conditions to differ materially from those indicated
in the forward-looking statements. Therefore, you should not rely
on any of these forward-looking statements. Important risk factors
that could cause actual results and financial conditions to differ
materially from those indicated in the forward-looking statements,
include among others: general economic, market and business
conditions in Canada and Australia; market volatility; unforeseen
delays in timelines for any of the transactions or events described
in this press release. All forward-looking information is qualified
in its entirety by this cautionary statement.
The
Company disclaims any obligation to revise or update any such
forward-looking statement or to publicly announce the result of any
revisions to any of the forward-looking information contained
herein to reflect future results, events or developments, except as
required by law.
Neither
the Canadian Securities Exchange nor its Regulation Service
Provider (as that term is defined in the policies of the Canadian
Securities Exchange) accepts responsibility for the adequacy or
accuracy of this release.
MindBio Therapeutics (CSE:MBIO)
Historical Stock Chart
From Aug 2024 to Sep 2024
MindBio Therapeutics (CSE:MBIO)
Historical Stock Chart
From Sep 2023 to Sep 2024